Top Medical News
HCV, HBV coinfection does not compromise HIV prognosis in the presence of active ART
an hour ago
Among people living with HIV on active antiretroviral therapy (ART), coinfection with the hepatitis B (HBV) or hepatitis C (HCV) viruses does not seem to significantly worsen immunologic and virologic response to treatment, a recent study has found.
Fatty liver more common in MAFLD than NAFLD
17 hours ago
Patients with metabolic dysfunction-associated fatty liver disease (MAFLD) see higher rates of fatty liver than those with nonalcoholic fatty liver disease (NAFLD), a recent study has found.
Fish oil products do not meet recommended EPA, DHA levels
19 hours ago
Serving sizes of different fish oil products do not usually provide adequate eicosapentaenoic acid (EPA) and docosehexaenoic acid (DHA) intake to deliver cholesterol-lowering benefits, according to a study.
Subcutaneous ICDs reduce complications without compromising shock effectiveness
20 hours ago
Implantation of subcutaneous implantable cardioverter defibrillators (S-ICDs) results in fewer perioperative, lead-related complications without offsetting the effectiveness of ICD shocks, reveals a study. However, S-ICDs lead to more early postoperative pain and inappropriate shocks.
Pembrolizumab extends RFS in stage II melanoma
22 hours ago
There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.
Any polyps spell risk of colorectal cancer
Patients with sporadic ampullary tumours more commonly have colorectal polyps or neoplasia than healthy controls, a recent study has found.
First-line serplulimab + chemo ups survival in extensive-stage SCLC
Roshini Claire Anthony, Yesterday

The addition of serplulimab to chemotherapy in the first-line setting improved overall survival (OS) in patients with extensive-stage small cell lung cancer (SCLC), according to results of the ASTRUM-005 trial.

Special Reports
01 Dec 2022
The recent ATTR-ACT long-term extension (LTE) study concluded that patients initially treated with tafamidis had significantly better survival than those initially treated with placebo, highlighting the significance of early diagnosis and treatment in transthyretin amyloid cardiomyopathy (ATTR-CM).
Optimising Treatment in Myelofibrosis Lead to Greater Benefits
01 Dec 2022
At the recent 19th Malaysian Society of Haematology Scientific Meeting 2022, Professor Dr Martin Griesshammer presented an overview of the current paradigm surrounding myelofibrosis (MF) treatment and evidence that points to earlier initiation with JAK inhibition being beneficial for intermediate-1 patients.
Viatris: Braving the Future with a Solid Legacy
01 Dec 2022
While Viatris is a relatively new name among the pharmaceutical players, it is by no means a newcomer. The company is the result of the merger between Mylan and Upjohn, a legacy division of Pfizer. With the experience and brand legacy of two iconic powerhouses, Viatris is well-equipped to tackle the future. MIMS Doctor speaks to Jeff Bote, country manager of Viatris Malaysia, and learns a little about their direction and aspirations for the future.
Early screening for genetic conditions among newborns may lead to early diagnosis and intervention, better patient outcomes
01 Dec 2022
Early screening of newborns provides them better chances of being diagnosed with serious genetic conditions and treated early. Two experts elaborate on the newborn screening (NBS) programme for serious genetic conditions in Malaysia.
A ray of light for patients with inflammatory bowel disease: Vedolizumab success story in a patient with ulcerative colitis
01 Dec 2022
IBD is a chronic condition that requires lifetime therapy, the safety and tolerability profile of vedolizumab is suitable for long-term treatment to maintain or improve the quality of life in patients with moderate-to-severely active UC.
Product Highlight - Amnoz
30 Nov 2022
Amlodipine 5 mg and 10 mg tab
Product Highlight - Cruzor
30 Nov 2022
Irbesartan 300 mg FC tab
Conference Reports
IV iron cuts risk of HF rehospitalization, CV death in ambulatory HFrEF patients
Audrey Abella, 02 Dec 2022
In a broad range of patients with HFrEF* and iron deficiency, the administration of IV ferric derisomaltose (FDI) was associated with a lower risk of recurrent hospitalization for heart failure (HHF) and cardiovascular (CV) death compared with standard of care (SoC), findings from the IRONMAN** trial have shown.
Chinese herbal med cuts MACCE in STEMI, but questions remain
Elvira Manzano, 01 Dec 2022
Tongxinluo, added to guideline-directed therapy, improves outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) in the large, multicentre CTS-AMI* study. But experts are clamouring for more evidence of efficacy.
Age, sex, syphilis risk factors for COVID-19 in PLHIV
Roshini Claire Anthony, 30 Nov 2022

Among people living with HIV (PLHIV), young women and patients with active syphilis appeared to be at an elevated risk of contracting COVID-19, according to a cross-sectional study presented at HIV Glasgow 2022.

FRESCO-2: Fruquintinib improves OS in heavily pretreated mCRC
Elaine Soliven, 30 Nov 2022
Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.
CT angiography may increase potential recipients of EVT for acute ischaemic stroke
Roshini Claire Anthony, 27 Nov 2022

Using collateral flow findings, as seen on computed tomographic (CT) angiography, may widen the population who can undergo late endovascular treatment (EVT) for acute ischaemic stroke (AIS), according to findings of the MR CLEAN-LATE trial.

No CV benefits with cooler dialysate
Elvira Manzano, 27 Nov 2022
The use of a cooler dialysate during maintenance haemodialysis does not offer cardiovascular (CV) benefits to patients in the MyTEMP trial.
Lower all-cause death, fewer HF events with empagliflozin in acute HF
Roshini Claire Anthony, 25 Nov 2022

Patients hospitalized with acute heart failure (HF) have a reduced risk of subsequent HF events or all-cause mortality if treated with once-daily empagliflozin while in hospital, according to results of the EMPULSE trial presented at HFSA 2022.